3rd Measuring Patient Engagement Summit

Memo

Patient engagement is no longer optional - it's a strategic imperative. Regulators expect defensible evidence, executives demand clear ROI, and tighter funding and portfolio scrutiny mean every engagement activity must demonstrate real value. Yet across the industry, organizations still struggle to prove the impact of their efforts. The 3rd Measuring Patient Engagement Summit is the only forum entirely focused on turning patient engagement strategies into measurable, credible impact. Over three days, 70+ senior leaders from pharma, biotech, and patient advocacy will convene to explore frameworks, tools, and practical approaches that show how patient input drives outcomes across development, access, and commercialization. Through immersive workshops, hands-on case studies, and collaborative discussions, you will:- Move beyond anecdotal reporting to defensible, outcome-based evidence- Benchmark strategies, co-create frameworks, and track patient impact across multi-year programs- Translate engagement into measurable influence for regulators, executives, and patient communities- Leave equipped with peer-tested approaches, practical frameworks, and actionable insights to elevate your patient engagement from activity to strategic, measurable value Measuring activity is no longer enough - demonstrating impact is what moves the industry forward. URLs:Brochure: https://go.evvnt.com/3467872-1?pid=5569Tickets: https://go.evvnt.com/3467872-2?pid=5569 Prices:Full Access Pass - Drug Developer: USD 4397.00,Conference Only - Drug Developer: USD 3099.00,Full Access Pass - Academic: USD 3797.00,Conference Only- Academic: USD 2699.00,Full Access Pass - Service Provider: USD 5397.00,Conference Only - Service Provider: USD 3899.00 Speakers: Dawn Aubel, Senior Director - Patient Centered Development, Cardiovascular, Renal and Metabolism, AstraZeneca, Deanine Halliman, Director - Clinical Development, Avidity Biosciences, Inc., Melissa Penn, Director - Patient Engagement, Research and Development, Bayer, Fatima Scipione, Vice President - Global Patient Affairs, Blueprint Medicines, Vanessa Boulanger, Director - Patient Experience and Engagement, Boehringer Ingelheim, Tiffany Valentine, Associate Director - Corporate Affairs, Patient Engagement, Global Purpose and Patient Experience, Bristol Myers Squibb, Shalome Sine, Senior Manager and Qualitative Insights Specialist, Center For Information and Study on Clinical Research Participation, Elsa Lavita, Senior Director - Patient Advocacy, Cullinan Therapeutics, Sonali Chopra, Executive Director - Patient Advocacy Relations, Genentech, Emma Sutcliffe, CPO, ISPEP, Caroline Allen, Head of Patient Advocacy and Communications, ITF Therapeutics, Tom Croce, Vice President - Global Patient Advocacy, Jazz Pharmaceuticals plc, Amy Mackey, Director - Patient Innovation and Engagement - Oncology, Merck and Co, Ify Osunkwo, Chief Patient Officer - Rare Disease, Novo Nordisk, Danielle Denison, Patient Engagement Lead - Hemophilia, Pfizer, Laura Russo, US Patient Engagement Lead, Pfizer, Maria Marano, Associate Program Director, PFMD, Hayley Chapman, Executive Director - Operations, PFMD, Pujita Vaidya, Director - Regulatory Science and Policy, Sanofi, Maggie Artica, Associate Director - Patient Engagement, Experience and Recruitment, Takeda Pharmaceutical, Karin Rosbeck, President and Chief Executive Officer, TSC Alliance Category: Conferences Date and Time: 5th May 2026 at 8:00 am to 7th May 2026 at 4:20 pm Venue details: The Colonnade, 120 Huntington Avenue, Boston, Massachusetts, 02116, United States